Completes

SUPPLEMENT

Charlotte’s Web Completes Filing of Prospectus Supplement for At-the-Market Equity Program | Cannabis

/NOT FOR DISTRIBUTION IN THE UNITED STATES/

ATM program adds optionality to capital liquidity toolbox

BOULDER, Colo., June 4, 2021 /CNW/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”) has filed a prospectus supplement to establish an at-the-market equity program (the “ATM Program”). The Company may distribute up to CAD$60 million of common shares of the Company (the “Offered Shares”) under the ATM Program. Any distributions of the Offered Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement (the “Distribution Agreement”) with Canaccord Genuity Corp. and BMO Nesbitt Burns Inc. (together, the “Agents”). The Offered Shares may be issued by the Company to the public from time to time, through the Agents, at the Company’s discretion. The Offered Shares sold under the ATM Program, if any, will be sold at the prevailing market price

Read More Read More
THERAPY

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline | Financing Agreements

PHILADELPHIA, March 3, 2021 /PRNewswire/ — Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing. The financing was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital. Founding investors Versant Ventures and Leaps by Bayer also participated. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

“We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century’s technology platform into the clinic,” said Lalo Flores, Chief Executive Officer, Century Therapeutics. “With this new investor partnership, we are well-positioned

Read More Read More